A single-cycle recombinant VSV vaccine displaying the Hendra virus glycoprotein uniformly protects against Hendra and Nipah virus challenge.

NPJ Vaccines · 2026 · PMC12827412 · PMID 41484102

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

Challenge with HeV or NiV-B following treatment did not significantly impact the resultant nAb titer; however, there was a slight trend towards increasing homologous PRNT50 titers (challenge with NiV-B increases NiV PRNT50, challenge with HeV increases HeV PRNT50).

also in 3,004 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.